Article Text

Download PDFPDF

1114 Targeted delivery of a potent STING agonist payload via an antibody drug conjugate drives robust antitumor activity in preclinical models
  1. Elizabeth Cummins1,
  2. David Gruber1,
  3. Weiping Zeng1,
  4. Michelle L Ulrich1,
  5. Kaleb Smith2,
  6. Mallory Long1,
  7. Kellie Spahr1,
  8. Katie Snead1,
  9. Katelyn Hinricher1,
  10. Aditi Langalia1,
  11. Priyanka Gupta3,
  12. Alyson J Smith1,
  13. Patrick Burke1,
  14. Shyra Gardai1,
  15. Peter Senter1,
  16. Adam Hill1 and
  17. Elizabeth Gray1
  1. 1Seagen Inc., Bothell, WA, USA
  2. 2Seagen Inc., Seattle, WA, USA
  3. 3Seagen Inc., Foster City, CA, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background STING is an innate immune pathway that detects intracellular DNA from foreign pathogens as well as stressed or tumor cells and activates a proinflammatory, type I interferon (IFN) response.1 STING activation is critical for mounting anti-viral immunity, and recent advances suggest this pathway can be co-opted to drive an anti-tumor immune response.2 However, STING activation requires careful and controlled agonism as dysregulated STING signaling is associated with autoinflammatory diseases including systemic lupus erythematosus (SLE), Aicardi-Goutières syndrome (AGS) and STING-associated vasculopathy with onset of infancy (SAVI).3 Balancing anti-tumor immunity against the risk of systemic immune activation has likely hindered the clinical success of systemic STING agonist small molecules.4 To date, STING agonist therapeutics have shown limited anti-tumor activity potentially due to their short half-life and poor retention within the tumor microenvironment (TME).5 We hypothesized that targeted delivery of a potent STING agonist to the tumor microenvironment via an antibody drug conjugate (ADC) may overcome these limitations.

Methods STING agonist ADCs were generated by conjugating novel, potent cleavable and non-cleavable drug-linkers to a tumor-targeting antibody. The potency of these STING agonist ADCs and released free drugs were evaluated on human myeloid cells in vitro. Finally, the antitumor activity of STING ADCs were evaluated in vitro in a tumor and immune cell co-culture system as well as in vivo in syngeneic murine tumor models.

Results STING agonist ADCs with both non-cleavable and cleavable drug-linkers demonstrated comparable potency in vitro – with a similar capacity to induce type I IFN signaling and elicit immune-mediated tumor cell killing. However, in vivo, STING agonist ADCs with the non-cleavable drug-linker led to superior antitumor activity compared to ADCs with cleavable drug-linkers. STING agonist ADCs with this novel, potent non-cleavable drug-linker demonstrated robust, durable antitumor activity across multiple tumor models as well as reduced systemic immune activation compared to a small molecule agonist.

Conclusions Here, we report the generation of a STING agonist ADC that elicits robust antitumor activity across multiple preclinical murine tumor models. Drug-linker design was critical for maximizing antitumor activity, as ADCs with the non-cleavable drug-linker drove enhanced antitumor activity compared to cleavable drug-linkers. This targeted ADC delivery led to antitumor activity with reduced systemic immune activation compared to a small molecule STING agonist. Altogether, these data demonstrate the potential of STING agonists as ADC payloads to drive tolerated, efficacious anti-cancer responses.

Ethics Approval All animal studies were conducted in accordance with protocols reviewed and approved by the Institutional Animal Care and Use Committee at Seagen or the external testing facility that conducted the studies.


  1. Ablasser A, Zhijian CJ, cGAS in action: Expanding roles in immunity and inflammation. Science. 2019;363(6431):eaat8657.

  2. Flood BA, Higgs EF, Li S, Luke JJ, Gajewski TF. STING pathway agonism as a cancer therapeutic. Rev. 2019;290(1):24–38.

  3. Ahn J, Barber GN. Self-DNA, STING-dependent signaling and the origins of autoinflammatory disease. Opin. Immunol. 2014;31:121–126.

  4. Aval LM, Pease JE, Sharma R, Pinato DJ. Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy. Clin. Med. 2022; 9:3323.

  5. Marc-Bernstam F, et al. Phase I dose-escalation trial of MIW815 (ASU-S100), an intratumoral STING agonist, in patients with advanced/metastatic solid tumors or lymphomas. Cancer Res. 2022; 28:677–688.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.